WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.
Info & Links
CEO
Paul B. Bolno
Headquarters
7 STRAITS VIEW #12-00, MARINA ONE EAST TOWER SINGAPORE, U0 018936, SINGAPORE
Wave Life Sciences Ltd. Ordinary Shares Statistics
Valuation Measures
Market Capitalization2
1.31B
Enterprise Value
1.10B
Enterprise Value/EBITDA(ttm)
-8.13
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
11.67
Price to Book(mrq)
9.26
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
100.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
-62.83%
Return on Equity(ttm)
-78.45%
Return on Invested Capital(ttm)
-93.18%
Return on Assets(ttm)
-41.51%
Income Statement
Revenue(ttm)
93.95M
Revenue Per Share(ttm)
0.59
Gross Profit(ttm)
93.95M
EBITDA(ttm)3
-134.84M
Net Income Available to Common(ttm)
-129.87M
Diluted EPS(ttm)
-0.90
Share Statistics
Beta (5Y Monthly)
-0.95
52-Week Change
30.95%
S&P 500 52-Week Change
20.28%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
159.14M
Dividend Yield
0.00%
Float4
118.26M
% Held by Insiders
23.98%
% Held by Institutions
89.73%
Balance Sheet
Total Cash(mrq)
208.48M
Total Cash Per Share(mrq)
1.31
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
2.56%
Quick Ratio(mrq)
2.95%
Book Value Per Share(mrq)
0.89
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.67
Free Cash Flow(ytd)
-109.52M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.